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Available online xxxxThe study was conducted to investigate the effects of dietary administrations of four nutraceuticals in dogs. Sev-
enty four dogswere enrolled in the trials, 24 healthy dogswere fedwith a control diet (CT) and the experimental
groups received for 60 days the same diet supplemented with nutraceuticals, namely Echinacea angustifolia (EA,
0.10 mg/kg live weight as echinacoside; 14 dogs), Vaccinium myrtillus (VM, 0.20 mg/kg live weight as
anthocyanidin, 13 dogs), Curcuma longa (CL, 6.60 mg/kg live weight as curcumin, 18 dogs with arthrosis), and
Sylibum marianum (SM, 1.5 mg/kg live weight as sylibin, 8 dogs with hepatopathy). Dogs were weighted at the
beginning of study and blood samples were collected at the beginning (T0) and at the end (T60) of the study.
VM signiﬁcantly down regulated TNF, CXCL8, NFKB1 and PTGS2 and decreased plasma ceruloplasmin (CuCp).
The activity of EA was evidenced by the signiﬁcant decrease of TNF and NFKB1 expression and CuCp levels and
by the increase of plasma Zn. Administration of CL caused a signiﬁcant decrease of CuCp and increase of Zn
and a down regulation of TNF, CXCL8, NFKB1 and PTGS2, corroborating the anti-inﬂammatory action of curcumi-
noids. After 60 days of treatmentwith SM, plasma ALT/GPT activity was reduced and paraoxonasewas increased,
supporting the antioxidant activity of silymarin, also conﬁrmed by the signiﬁcant up regulation of SOD2. Results
indicated that nutraceutical administrations in dogs can be an interesting approach to modulate immune re-
sponse in order to improve health condition of animals.
© 2016 Elsevier Ltd. All rights reserved.Keywords:
Dog
Nutraceuticals
Gene expression
Biomarkers1. Introduction
The inclusion of nutraceuticals in the diet of human, livestock and
companion animals has gained popularity (Colitti and Grasso, 2014;
Swanson et al., 2003) in the last decades and in the market there is a
large variety of supplements or foods containing a broad type of plant
extracts, pure compounds and, more in general, functional compounds.
Among the other, the activity of nutraceuticals can be directed towards
immune system, arthrosis, Alzheimer, obesity, ageing, oxidative stress,
depression, intestinal bowel disease and intestinal bowel syndrome or
metabolic syndrome (Wichtl, 2004). Often, the same nutraceutical has
several positive effects, as the case of curcumin (Ara et al., 2016;
Colitti et al., 2012) or resveratrol (Tomé-Carneiro et al., 2013; Woode
et al., 2015). According to the EU Regulation 1831/2003 (Regulation
(EC) No 1831/2003 of the European Parliament and of the Council of
22 September 2003) on additives for use in animal nutrition, only the
herbal extract registered in the annexes can be used for animals, and
the inclusion in this list has to follow a standard protocol. In the last
published list (Annex I list of additives Regulation (EC) No 1831/2003,
Released 18.04.2016), natural products are registered mainly in theral, Food, Environmental and
.technological category of sensory additives, subcategory “ﬂavouring
compounds: substances the inclusion of which in feedstuffs increases
feed smell or palatability”. Nevertheless, several petfoods have claim
for speciﬁc activities of natural products, but scientiﬁc evidences of
their beneﬁts are not always conclusive. To assess the activity of plant
nutraceutical, researches have published studies using laboratory ani-
mals or in vitro cell cultures (Farinacci et al., 2008; Farinacci et al.,
2009; Pomari et al., 2013; Pomari et al. 2014; Pomari et al., 2015;
Stefanon et al., 2015), and scientiﬁc evidences are also available for
companion animals (Colitti et al., 2012; Comblain et al., 2015).
Plants contain an almost inﬁnitive list of compounds with pharma-
cological and nutraceutical properties and in the present study we con-
centrated on 4 puriﬁed extracts, Vaccinium myrtillus, Curcuma longa,
Echinacea angustifolia and Sylibummarianum, with documented activity
for speciﬁc biological functions.
Vaccinium myrtillus (VM) is a shrub belonging to Ericaceae family
growing spontaneously in Europe, Northern Asia, Iceland, Canada and
United States. Its dry and powdered fruits and leaves have been used
in European traditional medicine for the treatment of many disorders.
It is generally named “Bilberry” or “European Blueberry” to distinguish
from “American Blueberry”. Anthocyanins chemical group, responsible
for the typical bilberry’ color, represent the main active compounds
contained in this fruit (Kähkönen et al., 2003),which have awell-recog-
nized antioxidant property. Among berries, bilberry or Vaccinium
Table 1
Number of dog allotted for the treatments in each of the four sites of study.
Group S0 K1 K2 K3 Total
CTRL 7 4 6 4 21
VM – 4 4 5 13
CL 6 3 – 9 18
EA 5 – 2 7 14
SM 5 3 – – 8
Total 23 14 12 25 74
CTRL = control; VM = Vaccinium myrtillus; CL = Curcuma longa; EA = Echinacea
angustifolia; SM= Sylibum marianum.
S0 = shelter; K1 = Kennel 1; K2 = Kennel 2; K3 = Kennel 3.
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most effective antioxidant activity (Nakajima et al., 2004).
Curcuma longa (CL), also known as turmeric, is a perennial plant of
the Zingiberaceae family and the rhizome contains compounds called
curcuminoids, which include curcumin (diferuloylmethane), demetho-
xycurcumin, and bisdemethoxycurcumin. Therapeutic uses suggested
for curcumin refer to a huge range of biological activities, like cancer
chemopreventive, antitumor and neuroprotective, primarily based on
its recognized antioxidant and anti-inﬂammatory properties
(Venugopal and Sudheer, 2007). Among the activities of CL, a strong
anti-inﬂammatory activity has been reported in dogs (Colitti et al.,
2012; Comblain et al., 2015).
Echinacea angustifolia (EA) is a perenneal herb belonging to
Asteraceae family, that includes 9 species, but only E. pallida, E.
angustifolia and E. purpurea have shown pharmacological properties.
American Indians were the ﬁrst to use Echinacea species for many dif-
ferent ailments, including cough, sore throat and tonsillitis (Caruso
and Gwaltney, 2005).
An extensive description of Echinacea genuswasmade in a study for
EFSA (European Food Safety Authority) evaluating its use as additive in
animal production. In particular, the report concerned Echinacea’ chem-
ical active constituents, pharmacology, toxicology and efﬁcacy either in
human than in veterinary studies (Franz et al., 2005). Most relevant
Echinacea active constituents, principally found in the roots, are
echinacoside, cichoric and chlorogenic acids, caffeic acid derivatives
and different polysaccharides like fructans, xyloglucans and
heteroxylanes. Among the 3 species, E. angustifolia shows the highest
concentration in phytochemicals, in particular echinacoside content, ab-
sent in the others (Senchina et al., 2006; Zhai et al. 2007). Known im-
mune modulatory effects of EA are the activation of macrophages
(Barrett, 2003) and polymorphonuclear granulocytes (Farinacci et al.,
2009), resulting in an increased phagocytic activity. This immune stim-
ulation activity of EA can be used not only to cope with infectious dis-
eases but also when stressful events temporary lowering immune
defenses (Sgorlon et al., 2012).
Silybummarianum (SL), also known asmilk thistle, is a biennial plant
of the Asteraceae family, which can be typically found in middle-south
European regions, where it grows spontaneously. The main active com-
ponent of SM is silymarin, a phytocomplex comprising different ﬂavo-
noids among which the most important are silybin, isosilybin,
silychristin and silydianin, concentrated in fruits and seeds (Pradhan
and Girish, 2006). Silymarin has several beneﬁcial actions useful in the
treatment of hepatobiliary disease, including antioxidant, anti-inﬂam-
matory, and antiﬁbrotic properties (Trappoliere et al., 2009; Verma
and Thuluvath, 2007), also in dogs (Vandeweerd et al., 2013).
The present study reports the results of a dietary intervention study
which involved the phytocomplexes of VM, CL, EA and SM. Pure extracts
were added to a semimoist complete diet and fed for 60 days to dogs to
assess the effects on plasma biochemical parameters and target gene ex-
pression in the peripheral leukocytes.
2. Materials and methods
2.1. Dog recruitments and allocation to groups
All dogs were adult and were recruited in one shelter and in three
kennels. The shelter (S0)was a private Dog Shelter under regular veter-
inary monitoring for clinical diseases and therapeutic protocols and the
dogs were for at least from 1 year hosted in the shelter. Kennel 1 (K1)
was a private kennel, with resident utility and defense working dogs.
Kennel 2 (K2) was a training center, where owners regularly carried
dogs for education and to reinforce physical conditions. Kennel 3 (K3)
was a facility for huntingdogs breeding,with someanimals regularly in-
volved in hunting sessions. Dogs were under the control of the respec-
tive veterinarian and all data were obtained from medical records,
including a standard complete physical examination performed by theveterinarians, which were asked to follow the dogs during the study.
All dogs had to fulﬁll the following criteria: aged N2 years, medium to
large size, resident in the shelter or attending regularly the kennels for
at least 1 year.
Within each site, the dogs with no evidence of clinical diseases for at
least 1 year and without any therapeutic protocol for at least 6 months
were considered healthy and randomly allotted to the control group
(CTRL) or to Echinacea angustifolia (Polinacea® - EA) group. Exclusion
criteria were the presence of infectious and parasitic diseases, systemic,
neurological or traumatic diseases or general symptoms of intolerance/
allergy to nutraceutical diets administered in this dietary intervention
study. Dogs actively involved in training were allocated to Vaccinium
myrtillus (VM) group, those with history of arthrosis were allocated to
Curcuma longa group (CL) and those suffering from liver diseases to
Sylibum marianum group (SM). At the end, according to dogs clinical
conditions and history and owners availability, a total of 74 dogs were
enrolled (Table 1), 23 hosted in the shelter (S0), 14 resident in K1, 25
resident in K3 and 12 regularly attending K2. Crossbreeds were the
most representative individual in S0 (18 dogs), whilst in K1 and K2
the majority of dogs were German Shepherd (11 dogs in K1 and 5 in
K2) and in K3 English Setter (21 dogs). Age, breed, sex and live weight
at the beginning of the study of all the dogs are reported in the Supple-
mentary Table 1.
2.2. Dietary Intervention Study
For the study, 5 diets were formulated to satisfy the nutrients re-
quirements according to NRC (2006) indications and produced in a
form of semi moist food. For the formulation, energy, protein, linoleic
acid, eicosopentaenoic acid, mineral and vitamins requirements were
considered. All the 5 diets contained the same ingredients with the
same proportions (Table 2), the only variation being the inclusion of
minerals and vitamins of the different diets according with the
nutraceuticals supplementation and the speciﬁc clinical conditions.
The commercial name of nutraceuticals, main active compounds, purity
and daily dose (mg/kg live weight) added to the experimental diets are
reported in Table 3. The nutraceuticals were purchased from Indena
(Indena Spa, Milan, Italy).
From to the beginning of the study, within each site dogs were fed
with different commercial diets. Starting from 15 days before the begin-
ning of the study, they were fed with the control diet (CTRL), consisting
of a semi moist canned food without inclusion of nutraceuticals. After
this adaptation period, each group received a different diet, as indicated
in Table 1, for 60 days. The amount of diet offered was calculated on the
basis of the live weight.
At the beginning (T0) and end (T60) of the study, blood samples
were collected in the morning just before meal from the cephalic vein
in 5 ml vacuum tubes with Li-heparin (Venoject, Terumo Europe N.V.,
Leuven, Belgium) and in PAXgene Blood RNA System tube (Preanalytix,
Hombrechtikon, Switzerland), for biochemical analysis and RNA extrac-
tion, respectively.
For biochemical analysis, blood was immediately refrigerated to 6–
8 °C, transported to the laboratory within 2 h and centrifuged at
Table 2
Ingredients and composition of the moist food used fed to the dogs during the study; for
the treated group, extracts were included in the supplement.
Item Unit Value
Ingredient
Water % As Fed 40.0
Chicken meat ” 14.0
Rice ” 8.0
Carrot, dehydrated ” 6.0
Turkey meat ” 6.0
Fish, herring ” 5.0
Oil, sunﬂower ” 3.0
Venison meat ” 3.0
Pork liver ” 3.0
Goose meat ” 3.0
Supplement ” 2.5
Oat ﬂakes ” 2.0
Potatos ﬂakes ” 2.0
Eggs, dehydrated ” 2.0
Fish oil ” 0.5
Composition
Water % 60.3
Protein %/DM 26.6
Fat ” 19.0
Crude ﬁber ” 2.2
Ash ” 3.5
Starch ” 35.0
Metabolizable energy Kcal/kg DM 4200
DM= dry matter.
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−20 °C until analysis. Blood collected in PAXgene blood RNA System
tubes was incubated at room temperature for 2 h for RNA stabilization
and then stored at−80 °C until analysis.
All the procedures and sample collections were in compliance with
the National legislation (Law 116/91) and internal ethical guidelines
down by the University of Udine as well as Public Veterinary Service
at the time the study was performed.
2.3. Biochemical and gene expression analysis
Urea, glucose, cholesterol, triglycerides, uric acid, creatin-kinase
(CK), alanine transferase (ALT/GPT), aspartate transferase (AST/GOT),
gamma glutamil transferase (gGT) were analysed using a Roche
Cobas® 6000 analyzer with proprietary kits (F. Hoffmann-La Roche
AG, Basel Switzerland). Plasma Zn was analysed with the Sentinel kit
(17640H, Sentinel CH. SpA, Milan, Italy). Plasma paraoxonase (PON) ac-
tivitywasmeasured by adapting themethod of Ferré et al. (2002) to the
ILAB 600 and ceruloplasmin was analysed according to the Cerón and
Martinez-Subiela (2004) method.
For genes expression evaluation, RNA was extracted from the
PAXgene blood RNA System tubes, following the manufacturer'sTable 3
Characteristics of the nutraceuticals and daily dose (mg/kg of liveweight) administered to
the dogs.
Group Latin name
Active compound
Daily dose of
extractName
% in the
extract
VM Vaccinium myrtillus Anthocyanidin 1 20
CL Curcuma longa Curcumin 20 33
EA Echinacea
angustifolia
Echinacoside 2 5
SM Sylibum marianum Sylibin 15 10
VM= diet supplemented with extracts of Vaccinium myrtillus; CL = diet supplemented
with extracts of Curcuma longa; EA = diet supplemented with extracts of Echinacea
angustifolia; SM= diet supplemented with extracts of Sylibum marianum.instructions. RNA concentrationwasmeasuredwith a spectrophotome-
ter (NanoDrop 1000 ThermoScientiﬁc, Wilmington, DE, USA), resulting
in a purity of 1.8–1.9. RNA integrity was evaluated through the observa-
tion of 18S and 28S ribosomal bands after electrophoresis on 1% agarose
gel, in the presence of GelRed (Biotinum, Aurogene, Rome, Italy) and
further checked using an Agilent Bioanalyser and the RNA nano Lab
chip kit (Bioanalyser Nanochip QC, USA).
A Primer3 Input software (Rozen and Skaletsky, 2000) was used to
design the primer sequences encoding for actin beta (ACTB), mitochon-
drial ribosomal protein S7 (MRPS7), C-X-C motif chemokine ligand 8
(CXCL8), nuclear factor kappa B subunit 1 (NFKB1), mitochondrial su-
peroxide dismutase 2 (SOD2), prostaglandin-endoperoxide synthase 1
(PTGS1), prostaglandin-endoperoxide synthase 2 (PTGS2), peroxisome
proliferator activated receptor gamma (PPARG), interferon gamma
(IFNG), nitric oxide synthase 2 (NOS2), BCL2 associated X protein
(BAX), BCL2 like 1 (BCL2L1), B-cell CLL/lymphoma 2 (BCL2), nuclear re-
ceptor subfamily 3 group C member 1 (NR3C1), nuclear receptor sub-
family 3 group C member 2 (NR3C2), cytochrome P450 family 11
subfamily B member 2 (CYP11B2), cytochrome P450 family 21 subfam-
ily A member 2 (CYP21A2), cytochrome P450 family 3 subfamily A
member 4 (CYP3A4), glutathione S-transferase alpha 3 (GSTA3) and
Tumor Necrosis Factor alpha (TNF). Primers were designed on Canis
lupus familiaris sequences, based on UniGene (NCBI; build number
13). Primers and product lengths for each gene are listed in Table 4 ac-
cording to the HUGO Gene Nomenclature Committee (HUGO Gene No-
menclature Committee at the European Bioinformatics Institute http://
www.genenames.org/).
2.4. Reverse transcription
Reverse transcriptions were performed with 400 ng of total RNA
using Improm-IITM Reverse Transcriptase system (Promega, Milan,
Italy). Total RNA samples with 1 μl random hexamers (0.5 μg/μl MBI
Fermentas, Italy) and free nuclease water to a ﬁnal volume of 20 μl
were incubated at 70 °C for 5min in a PTC-100TM thermocycler (MJ Re-
search Inc. Waltham, MA USA). Then, a mix was prepared with 4 μl of
Improm-II Reverse Transcriptase buffer (5X Promega, Milan Italy),
2.4 μl MgCl2 (50 mM), 1 μl of Improm-II Reverse Transcriptase and
1 μl of dNTP (10 mM) was added to the reaction and incubated at
37 °C for 90 min and ﬁnally at 94 °C for 5 min.
The ﬁnal cDNA concentration was assumed as 20 ng/μl.
2.5. Quantitative real-time polymerase chain reaction (qRT-PCR)
An aliquot of each cDNA samples were pooled and standard curves
with serial dilution of pool were used for each gene to optimize PCR
conditions and to calculate efﬁciency, ﬂuorescence baseline and thresh-
old. The qRT-PCRs were performed in triplicate form using Platinum®
SYBR® Green qPCR SuperMix-UDG (InvitrogenTM, Milan Italy). For
these reactions, a master mix with the following components was pre-
pared to the indicated end concentration: 0.5 μl of cDNA, forward and
reverse primers, 6.25 μl of 2X Platinum SYBR Green qPCR SuperMix-
UDG and water to a total volume of 12.5 μl. cDNA concentrations and
primers molarities were different for each gene and determined with
standard curves analyses performed before RT-PCR reactions. The PCR
ampliﬁcations were conducted applying 40 cycles (10 s at 95 °C, 30 s
at the speciﬁc annealing temperature, 30 s at 72 °C) in a 96-well spec-
troﬂuorometric thermal cycler (CFX-96TM, BioRAD, Hercules, Califor-
nia). The melting curve analysis of ampliﬁcation products was
performed at the end of each PCR reaction to conﬁrm that a single PCR
product was detected.
The expression of target genes was normalized using the ACTB and
MRPS7 genes and ΔCts were calculated by the difference between Ct
of genes target and the geometric mean of the two housekeeping
genes. The expression level of a given target gene in each experimental
groupwas analysed by the 2-ΔΔCt method (Bustin et al., 2009; Livak and
Table 4
Primer pair sets and parameters used in the real time PCR analysis.
Gene Genbank accession number Sequence (5′ → 3′) Product length, bp Ta (°C)
ACTB 5597004 For: ACTGGGACGACATGGAGAAG
Rev: AAGGCGTACCCCTCGTAGAT
280 59
MRPS7 73965035 For: CGCAAC CCCTATGTCATCTT
Rev: CAACTTCTCTGGCATCAGCA
201 57
CXCL8 415265 For: TCTTGGCAGCTTTTGTCCTT
Rev: GGGCCACTGTCAATCACTCT
151 57
NFkB1 50080137 For: TACCCCCAGGTCAAAATCTG
Rev: CTCTGTCATTCGTGCTTCCA
237 57
SOD2 50978897 For: CTAAGGGTGGTGGAGAACCA
Rev: AAGCGTCCCTGCTCCTTATT
240 58
PTGS2 13641174 For: ATCCCCTTCCTGCGAAATAC
Rev: CATCAGGTACAGGGGGAAGA
160 57
PTGS1 402743309 For: TGCTCATGCGTCTGGTACTC
Rev: GTCTGGCAACTGCTTCTTCC
188 57
PPARG 103472123 For: GGATTTCTCCAGCATTTCCA
Rev: GAGTTGGAAGGCTCTTCGTG
195 57
IFNG 50978905 For: CGGTGGGTCTCTTTTCGTAG
Rev: TCCCTCTTACTGGTGCTGCT
198 59
NOS2 925115237 For: GGAGGAGCAGCTACTGTTGG
Rev: GTCATGAGCAAAGGCACAGA
178 57
BAX 27372189 For: CATGGAGTTGCAGAGGATGA
Rev: CCTTGAGCACCAGTTTGCT
152 57
BCL2L1 50978741 For: ACCTGACATCCCAGCTTCAC
Rev: CGATCCGACTCACCAATACC
180 59
BCL2 50950156 For: ATGTGTGTGGAGAGCGTCAA
Rev: CCTTCAGAGACAGCCAGGAG
188 59
NR3C1 730321601 For: TCTGCCTCGTGTGTTCTGAC
Rev: GCTTCCAAGTTCATCCCAGC
214 58
NR3C2 928154864 For: GTCACCATCCTGGAGAGCAT
Rev: CAGCTCAAGGCAAATGATGA
233 57
CYP11B2 545521058 For: CCTTGTGGATGACTCTGT
Rev: GGTAGTTCTGCAGCACCACG
223 57
CYP21A2 55742761 For: GAGCACTGGTCCATCCAAAT
Rev: GTGTCCTTCGAGGAGCTGT
237 56
CYP3A4 928136586 For: TACCTGCCTTTTGGAACTGG
Rev: ACAATGGGCTTTTCAGGTTG
176 58
GSTA3 23452498 For: ATGCCCACCTGATCAAAAAG
Rev: CTTCAGCAGAGGGAAGTTGG
214 57
TNF 167765472 For: ACCACACTCTTCTGCCTGCT
Rev: CTGGTTGTCTGTCAGCTCCA
219 58
For, forward; Rev, reverse; Ta, annealing temperature.
145S. Sgorlon et al. / Research in Veterinary Science 109 (2016) 142–148Schmittgen, 2001) where the 2−ΔΔCt represents the difference of a
given target gene between each treated group (CTRL, VM, CL, EA and
SM) at T0 vs CTRL group at T0. The same analysis was done at T60.
The n-fold expression of a given target gene was calculated as log(2)
(ratio).
2.6. Statistical analysis
Statistical analysis of biochemical data were analysed using a mixed
model, with ﬁxed effect of time of sampling (T0 and T60), treatment
(CTRL, VM, CL, EA and SM) and their interaction, with animal repeated
within time and the random effect of site of sampling (S0, K1, K2 and
K3). Estimated marginal means were calculated and reported in the ta-
bles. For expression data, a general linearmodel was used, withﬁxed ef-
fect of treatment (CTRL, VM, CL, EA and SM) and random effect of site of
sampling. The SPSS (SPSS, 1997) package was used for computations
and means were considered to signiﬁcantly differ for P b 0.05.
3. Results
During the experimental period animals ingested the complete diets
without refusals, allowing optimal feeding conditions and availability of
nutrients. The biochemical parameters that resulted signiﬁcantly differ-
ent between the 5 groups or between days of sampling are reported in
Table 5.The activity of ALT/GPTwashigher (P b 0.01) in the SMgroup than in
the other groups and at T0 in comparison to T60 (P b 0.01). Effect of the
time of sampling was also evident, with a signiﬁcantly lower activity of
the enzyme at T60 (P b 0.01). The interaction of the ﬁxed effects was
also highly signiﬁcant (P b 0.01), as the ALT activity only in the SM
group decreased from T0 to T60. The mean values of PON did not
show signiﬁcant variation between treatments, whilst signiﬁcantly in-
creased (P b 0.01) at T60 in comparison to T0. A signiﬁcant interaction
was also observed (P b 0.01), since in the VM group the PON values in-
creased at T60 in comparison to T0. The CTRL and SM groups showed
lower values of CuCp (P b 0.01) in comparison to VM, CL and EA groups,
and themeans at T0were higher (P b 0.01) than at T60. Also for this var-
iable, the interaction was highly signiﬁcant (P b 0.001) and the mean
values in the VM, CL and EA groups were lower at T60 than at T0. The
plasma concentration of Znwas not affected by treatment, but increased
from T0 to 60 (P b 0.01). A signiﬁcant effect of the interaction was evi-
dent only in CL and EA groups, where the mean Zn values were higher
(P b 0.01) at T60 in comparison to T0. No signiﬁcant effect of time of
sampling and treatments were calculated for urea, glucose, cholesterol,
triglycerides, uric acid, CK, AST/GOT and gGT.
The n-fold values for the genes that resulted signiﬁcantly different
between the 5 groups are reported in Table 6. In comparison to the
CTRL group, a signiﬁcant (P b 0.05) down regulation of TNF was ob-
served in VM, CL and EA groups; instead the mean value of TNF in SM
groupwas not different from the other groups. The same signiﬁcant dif-
ferences between groups were reported for NFKB1 (P b 0.01); instead,
Table 5
Estimated means for the biochemical parameters measured in the plasma of dogs at the
beginning (T0) and at the end (T60) of the dietary intervention study to assess the effect
of nutraceutical administrations.
Item
ALT
PON CuCp Zn
U/l mg/l μmol/l μmol/l
Treatment
CTRL 45.8 B 134.7 NS 1.23 B 26.0 NS
VM 35.9 B 133.7 NS 1.67 A 24.8 NS
CL 39.2 B 139.3 NS 1.78 A 23.2 NS
EA 42.9 B 134.6 NS 1.54 A 27.9 NS
SM 77.0 A 118.6 NS 1.20 B 24.7 NS
Day of sampling
T0 54.7 A 126.2 B 1.72 A 23.0 B
T60 41.6 B 138.1 A 1.25 B 27.6 A
Interaction
CTRL – T0 48.7 B 130.0 CD 1.22 CD 25.7 B
CTRL – T60 42.9 BC 139.5 ABC 1.24 CD 26.4 B
VM – T0 36.9 C 114.6 E 1.86 B 24.7 BC
VM – T60 35.0 C 152.7 A 1.48 C 24.9 BC
CL – T0 39.7 BC 145.5 AB 2.22 A 19.4 C
CL – T60 38.7 BC 133.1 BC 1.33 CD 26.9 B
EA – T0 43.6 BC 128.9 CDE 1.98 AB 21.5 BC
EA – T60 42.3 BC 140.3 ABC 1.11 D 34.2 A
SM – T0 104.7 A 111.8 E 1.33 CD 23.8 BC
SM – T60 49.3 B 125.4 CDE 1.08 D 25.7 B
Effects, sig of P
Treatment *** NS *** NS
Day of sampling *** *** *** ***
Interaction *** *** *** **
Random effect of site NS NS NS NS
MSE 297.5 468.0 0.16 68.52
CTRL = control group; VM = diet supplemented with extracts of Vaccinium myrtillus;
CL = diet supplemented with extracts of Curcuma longa; EA = diet supplemented with
extracts of Echinacea angustifolia; SM = diet supplemented with extracts of Sylibum
marianum; ALT = alanine transferase; PON = paraoxonase; CuCp = ceruloplasmin;
Zn = zinc.
***P b 0.001; **P b 0.01; A, B, C, D, E on the same column denote signiﬁcant differences for
P b 0.001 or P b 0.01; NS: not signiﬁcant.
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CL groups and up regulated in EA group in comparison to CTRL group.
The relative gene expression of PTGS2 in VM and CL groups was signiﬁ-
cantly down regulated (P b 0.01) in comparison to EA and CTRL groups.
The n-fold values in SMgroup signiﬁcantly differ only from CL group. An
up-regulation of SOD2was evident in VM, CL and SM groups (P b 0.05)
in comparison to CTRL group and the EA group was signiﬁcantly differ-
ent only from CL and SM groups. For all themeasured gene expressions,
no signiﬁcant effect of site of sampling was observed.Table 6
Gene expressions in thewhite blood cells of dogs at the end (T60) of the dietary intervention stu
in comparison to the beginning of the study (T0).
Treatment TNF se CXCL8 se NFKB1
Mean Mean Mean
CTRL 0.58 0.32 a 0.14 0.46 b 0.06
VM −0.60 0.38 b −1.86 0.54 c −1.62
CL −1.02 0.34 b −1.96 0.46 c −2.47
EA −0.79 0.39 b 2.68 0.54 a −1.62
SM −0.05 0.52 ab −0.45 0.71 bc −0.20
Effect
Treatment * * ***
Site NS NS NS
CTRL= control group; VM= diet supplemented with extracts of Vacciniummyrtillus; CL= die
Echinacea angustifolia; SM= diet supplemented with extracts of Sylibum marianum.
TNF= tumor necrosis factor alpha; CXCL8=C-X-C motif chemokine ligand 8; NFKB1=nuclea
tochondrial superoxide dismutase 2.
*P b 0.05; ***P b 0.001; a, b, c on the same column denote signiﬁcant differences for P b 0.05; AThe effect of treatments was not signiﬁcant for PTGS1, PPARG, IFNG,
NOS2, BAX, BCL2L1, BCL2, NR3C1, NR3C2, CYP11B2, CYP21A2, CYP3A4
and GSTA3 expressions.
4. Discussion
Research with dogs has some critical points, since it is not easy to
ﬁnd large number of individuals homogeneous for breed, age, sex, feed-
ing regimes and environmental conditionswithin one location. Another
aspect is the need to reduce the number of animals for experiments (3R
Regulation, Directive 2010/63/EU), a common problem for all the ani-
mals, but especially in the case of companion animals. For these reasons,
often the studywith companion animals ismore anobservational study,
inwhich the variables are not under complete control for the ethical and
logistic issues reported above. In the present study, to control the resid-
ual variability we used amulticenter randomized design, by allocating a
control group in each of the 4 locations and applying a mixedmodel in-
cluding the random effect of the locations. Due to the very limited num-
ber of studies published about the use of these compounds in dogs, and
to the limitations imposed by ethical constraints to perform bioavail-
ability study and dose response experiments, the amount of extracts ad-
ministered to the animals corresponded to the dosage recommended by
the supplier (INDENA, Milan, Italy) for humans. Moreover, SM and CL
were provided in form of phytosome complex, to enhance bioavailabil-
ity of active compounds (Filburn et al., 2007; Kidd, 2009).
Anthocyanins chemical group, responsible for the typical bilberry’
color, represents the main active compound contained in this fruit,
which have a well-recognized antioxidant property (Kähkönen et al.,
2003). Among berries, bilberry or Vaccinium myrtillus specie is the
richest in anthocyanins, furthermore showing themost effective antiox-
idant activity (Nakajima et al., 2004). A wide range of bilberry extract
dosages has been used in humans (Monograph, 2001) and the only di-
etary intervention study in Alaskan Husky dogs only reported a daily
supplementation of 20 g of raw blueberries (Vaccinium angustifolium)
for 2 months (Dunlap et al., 2006). No indication of active compounds
concentration was reported, but the supplementation resulted effective
in blood antioxidant activity after dog exercise. The signiﬁcant increase
of PON and theup regulation of SOD2observed in the present study sup-
port the antioxidant effect of bilberry extract, as also reported in human
(Nile and Park, 2014). Besides to the antioxidant activity, bilberry also
demonstrated anti-inﬂammatory properties in macrophages, down
regulating the expression of IL1b, PTGS2, TNF, CCL22 (Chen et al.,
2008) and NFKB (Lee et al., 2014). This anti-inﬂammatory activity is
conﬁrmed by the signiﬁcant down regulation of TNF, CXCL8, NFKB1
and PTGS2 and by the signiﬁcant decrease of the positive acute phase
protein CuCp.
In vitro and in vivo animal studies have demonstrated the ability of
various Echinacea preparations to enhance the activities of immunedy to assess the effect of nutraceutical administrations. Values are reported as log2(n-fold)
se PTGS2 se SOD2 se
Mean Mean
0.34 A 0.32 0.41 A 0.23 0.40 c
0.39 B −1.72 0.48 BC 1.47 0.47 ab
0.35 B −2.12 0.43 C 1.64 0.42 a
0.41 B 0.46 0.50 A 0.59 0.48 bc
0.54 AB −0.16 0.66 AB 2.21 0.64 a
*** *
NS NS
t supplemented with extracts of Curcuma longa; EA= diet supplemented with extracts of
r factor kappa B subunit 1; PTGS2=prostaglandin-endoperoxide synthase 2; SOD2=mi-
, B, C on the same column denote signiﬁcant differences for P b 0.01. NS: not signiﬁcant.
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tions (Franz et al., 2005). Echinacea immunomodulatory activity
displays 2 main routes, being the ﬁrst the modulation of immunocom-
petent cells and the second a cellular anti-inﬂammatory activity, espe-
cially during bacterial or viral infections (Hudson et al., 2011).
In dogs, the only study on immune modulatory effect of Echinacea
showed that dietary treatment with this plant extract caused an in-
crease of phagocytic activity and IgM (Torkan et al., 2015). However,
the authors did not report any information about the species of Echina-
cea and the part of the plant used in the trial. Furthermore, the placebo
and the experimental groups before treatment showed signiﬁcantly dif-
ferent means for these variables. Studies in humans (Guiotto et al.,
2008) demonstrated a dose dependent down regulation of Echinacea
purpurea on pro-inﬂammatory cytokines CXCL8, IL6, IL10 and TNF. A sig-
niﬁcant upregulation of IL8 subsequent to treatment with Polinacea®
was reported in neutrophils by Farinacci et al. (2009) and in humans
by Dapas et al. (2014). The chemokine IL8was signiﬁcantly upregulated
also in ex-vivo stimulated human blood cells obtained from volunteers
orally treated with Echinacea purpurea (Ritchie et al., 2011). In the pres-
ent study, the administration of Polinacea® leaded to an upregulation of
CXCL8, which is a strong chemoattractant and angiogenic factor. This re-
sult suggests a positive role of EA in the stimulation of the immune sys-
tempromoting neutrophil activation possibly through the up regulation
of CXCL8mRNA levels. The anti-inﬂammatory activity of EA, at least in
healthy dog, is conﬁrmed in the present study, by the signiﬁcant down
regulation of TNF and NFKB1 and by the signiﬁcant decrease of the pos-
itive acute phase protein CuCp and by the increase of plasma Zn levels.
As reported by Mariani et al. (2006), circulating Zn levels are inversely
correlated to IL6,CXCL8 and TNF.
Therapeutic uses suggested for curcumin refer to a huge range of bi-
ological activities, like cancer chemopreventive, antitumor and neuro-
protective, primarily based on its recognized antioxidant and anti-
inﬂammatory properties (Oliveira et al., 2015). Curcumin is known to
protect cell membranes against the peroxidative damage caused by Re-
active Oxigen Species (ROS) produced during cellular breathing. Lipid
peroxidation is known to be a free-radical-mediated chain reaction
leading to cell membrane damages but primarily to oxidative stress,
which can result in severe metabolic dysfunctions, included inﬂamma-
tion (Venugopal and Sudheer, 2007). The antioxidant activity of
curcumin has been observed in neutrophil cells during inﬂammatory
activation with PMA (phorbol myristate acetate), with a suppression
of superoxides production and inhibition of cell adhesion, events asso-
ciated with the setting up of the inﬂammatory response (Farinacci et
al., 2009). In the present study, the CL dogs at T0 showed a signiﬁcant
higher CuCp and lower Zn concentrations in comparison to CTRL,
supporting the diagnosis of arthritis. The anti-inﬂammatory activity of
curcumin is conﬁrmed, since after 60 days of CL administration, the
mean values of these parameters were similar to the CTRL group. The
signiﬁcant down regulation of TNF, CXCL8, NFKB1 and PTGS2 observed
after 60 days of CL supplementation corroborates the effectiveness of
curcuminoids in reducing the inﬂammatory process. These results
agree with those of Colitti et al. (2012) obtained in dogs affected by os-
teoarthritis supplemented with curcumin or a NSAIDS PTGS2 selective
inhibitor. In that study, dogs received daily 4 mg or 5 mg/kg body
weight of curcumin or NSAIDS respectively, for 20 days. As expected
both molecules signiﬁcantly down regulated TNF gene expression, but
only curcumin acted as a suppressor of genes related to macrophages
proliferation. Moreover, CL up regulated the IkB kinase enzymatic com-
plex, responsible for the NFKB inactivation by trapping it in the cyto-
plasm of cells. The clinical outcome of the 18 dogs after 60 days of CL
was considered in terms of absence of pain to palpation, voluntary ac-
tivity, gait and stiffening of the leg, in comparison to T0. Considered the
limited number of subjects, no statistical analysis was carried out, but
interestingly for 10 dogs symptoms were reduced and in 2 disap-
peared; no anti-inﬂammatory drugs were required in the period of
the study. These clinical data conﬁrm those previously reported(Colitti et al. 2012) using the same standardized extract of Curcuma
longa.
Silymarin has several beneﬁcial actions useful in the treatment of
hepatobiliary disease, including antioxidant, anti-inﬂammatory, and
antiﬁbrotic properties (Pradhan and Girish, 2006; Verma and
Thuluvath, 2007). In an extensive clinical review on Silymarin's proper-
ties Wellington and Jarvis (2001) explained which are the different
mechanisms involved in its biological activity. They indicated the in-
creasing in the synthesis of ribosomal RNA (rRNA) species through
stimulation of polymerase I and rRNA transcription (thereby increasing
the synthetic rate of structural and functional proteins), the blockage of
the uptake of toxins such as α-amanitin from Amanita phalloides (the
deathcapmushroom), and the protection of the cellmembrane fromos-
motic stress and radical-induced damage. In the present study, the
group of dogs allotted to SM treatment suffered from liver diseases as
also conﬁrmed by higher plasma ALT activity at T0 (Table 5). The signif-
icant reduction of this enzyme activity at T60 is consistent with the
well-known liver protectant activity, which was observed also by
Fehér et al. (2015) and Liu et al. (2013). According to Kidd (2009), an-
other important function of SM is the antioxidant activity, conserving
glutathione in liver cells and protecting cell membranes against reactive
oxygen species. PON-1 is an important serum enzyme synthesized by
the liver involved in lipid metabolism, membrane stability and control
of oxidative stress (Holvoet, 2008; Varzi et al., 2007). Studies in dogs in-
fected with ehrlichiosis (Karnezi et al., 2016) and with induced
endotoxiemia (Tvarijonaviciute et al., 2012) have reported a reduction
of PON activity and an increase of positive acute phase protein. The sig-
niﬁcant increase of PON after SM administration, observed in the pres-
ent study, supports the antioxidant activity of silymarin that is
corroborated by the signiﬁcant up regulation of mitochondrial SOD2.
This is one of the main physiological defense mechanisms against free
radicals, which is subject to depletion during a period of toxic substance
overload (Holvoet, 2008). It was reported that in vitro incubation with
silymarin in a concentration equivalent to the usual therapeutic dosage
markedly increased the SOD in lymphocytes of patients with alcoholic
cirrhosis (Abenavoli et al., 2010). However, the limited number of
dogs in this group does not allow to draw conclusions from a clinical
point of view, but biochemical andmolecular outcomes suggest the use-
fulness of this nutraceuticals in the hepatopathies.
In conclusion, present data indicated that the nutraceutical adminis-
tration in dogs can be an interesting approach to modulate immune re-
sponse in order to improve health condition of animals. In particular,
VM and CL showed a signiﬁcant anti-inﬂammatory activity and, in addi-
tion, VMdisplayed antioxidant properties. The results of EA conﬁrm the
known immune systemmodulation. SM showed signiﬁcant antioxidant
and liver protectant activities. On the basis of these preliminary results
the tested compounds can be claimed for their biological activity in
dogs, in petfood formulation.
Supplementary data to this article can be found online at doi:10.
1016/j.rvsc.2016.10.005.
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